Carvedilol versus Propranolol in Preventing Decompensation in Patients with Compensated Cirrhosis: A Real-World Propensity-Matched Study
Journal of Gastrointestinal and Liver Diseases · 2025
DOI: 10.15403/jgld-6497 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Gastrointestinal and Liver Diseases, 2025. Verfasst von Hussam Almasri und 8 weiteren Autor:innen. Beteiligte Einrichtung: University of North Dakota School of Medicine and Health Sciences, Fargo, ND, USA. hussamalmasri10@gmail.com. Hauptthemen laut MEDLINE: Carvedilol, Propranolol, Liver Cirrhosis, Adrenergic beta-Antagonists. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background and Aims: Non-selective beta-blockers are widely used for the management of portal hypertension and prevention of variceal bleeding in patients with liver cirrhosis. While studies have demonstrated carvedilol‘s superiority in reducing portal pressure compared to propranolol, limited real-world data directly compare their efficacy in preventing decompensation.
Methods
We conducted a retrospective cohort study using the TriNetX database on patients from several healthcare organizations in the US Collaborative Network. Cohorts were defined as adult patients with compensated cirrhosis who were prescribed either carvedilol or propranolol. Propensity score matching was applied to balance demographic, clinical, and laboratory characteristics. The first decompensation event, all-cause hospitalization, and all-cause mortality were defined as outcomes.
Results
After matching, each cohort included 12,890 patients. The mean age was 59.6 years. Comorbidities and laboratory findings were well-balanced between the two groups. Patients receiving carvedilol had a significantly lower risk of developing new decompensating events within five years, including ascites, variceal bleeding, hepatic encephalopathy, and hepatorenal syndrome. Spontaneous bacterial peritonitis was not significantly different between the groups. Post-matching analysis showed marginally reduced all-cause mortality in the carvedilol group at five years.
Conclusions
In this real-world study, carvedilol demonstrated superior efficacy compared with propranolol in reducing key decompensatory events in patients with compensated cirrhosis, likely due to its enhanced ability to lower portal pressure. However, the mortality benefit probably requires further studies to unfold.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University of North Dakota School of Medicine and Health Sciences, Fargo, ND, USA. hussamalmasri10@gmail.com.
- Beth Israel Lahey Health Inc., Cambridge, MA, USA. alibutt95@gmail.com.
- University of Minnesota Twin Cities, Minneapolis, MN, USA. rahulkarnagovind@gmail.com.
- University of North Dakota School of Medicine and Health Sciences, Fargo, ND, USA. gssidhu14@gmail.com.
- Allegheny Health Network Graduate Medical Education, Pittsburgh, PA, United States. himsikhar@gmail.com.
- Sanford Health, Fargo, ND, USA. john.bassett@sanfordhealth.org.
Zitieren
APA
Almasri, H., Butt, M. A., Karna, R., Sidhu, G., Khataniar, H., Bassett, J. T., Malik, R., Lin, M. V., & Mohy-Ud-Din, N. (2025). Carvedilol versus Propranolol in Preventing Decompensation in Patients with Compensated Cirrhosis: A Real-World Propensity-Matched Study. Journal of Gastrointestinal and Liver Diseases. https://doi.org/10.15403/jgld-6497
Vancouver
Almasri H, Butt MA, Karna R, Sidhu G, Khataniar H, Bassett JT, et al. Carvedilol versus Propranolol in Preventing Decompensation in Patients with Compensated Cirrhosis: A Real-World Propensity-Matched Study. Journal of Gastrointestinal and Liver Diseases. 2025. doi:10.15403/jgld-6497
BibTeX
@article{Almasri2025,
author = {Almasri, Hussam and Butt, Muhammad Ali and Karna, Rahul and Sidhu, Guneet and Khataniar, Himsikhar and Bassett, John T and Malik, Raza and Lin, Ming Valerie and Mohy-Ud-Din, Nabeeha},
title = {Carvedilol versus Propranolol in Preventing Decompensation in Patients with Compensated Cirrhosis: A Real-World Propensity-Matched Study},
journal = {Journal of Gastrointestinal and Liver Diseases},
year = {2025},
doi = {10.15403/jgld-6497}
}
EUVIMED